AKT1 and non-small cell lung carcinoma: Over the past decade, several inhibitors targeting AKT have been developed and displayed promising anti-cancer activity in NSCLC, such as ATP-competitive protein kinase inhibitors, inhibitors of phosphatidylinositol-3,4,5-trisphosphate binding, and other allosteric inhibitors21, 22, 23.